Abstract

A 43-year-old women admitted to our hospital for weight loss, anorexia, and abdominal pain was diagnosed with sigmoid neoplasm and multiple bilobar liver metastases. This patient received six cycles of systemic FOLFOX prior to a laparoscopically assisted anterior resection of the rectosigmoid for a poorly differentiated invasive adenocarcinoma T2N2M1, K-RAS negative (wild type). Hepatic arterial infusion (HAI) of L-folinic acid modulated 5-fluorouracil (LV/5-FU) with intravenous (iv) irinotecan (FOLFIRI) and cetuximab as adjuvant therapy resulted in a complete metabolic response (CR) with CEA normalization. A right hepatectomy extended to segment IV was performed resulting in (FDG-)PET negative remission for 7 months. Solitary intrahepatic recurrence was effectively managed by local radiofrequent ablation following 6c FOLFIRI plus cetuximab iv. Multiple lung lesions and recurrence of pulmonary and local lymph node metastases were successfully treated with fractionated stereotactic radiotherapy (50 Gy) and iv LV/5-FU/oxaliplatin (FOLFOX) plus cetuximab finally switched to panitumumab with CR as a result. At present the patient is in persistent complete remission of her stage IV colorectal cancer, more than 5 years after initial diagnosis of the advanced disease. Multidisciplinary treatment with HAI of chemotherapy (LV/5-FU + CPT-11) plus EGFR-inhibitor can achieve CR of complex unresectable LM and can even result in hepatectomy with possible long-term survival.

Highlights

  • The 5-year survival rate of patients with advanced colorectal cancer (CRC) that has metastasized to the liver is determined by the possibility of resection of the primary tumor and liver metastases (LM)

  • Multiple lung lesions and recurrence of pulmonary and local lymph node metastases were successfully treated with fractionated stereotactic radiotherapy (50 Gy) and iv LV/5-FU/oxaliplatin (FOLFOX) plus cetuximab switched to panitumumab with complete metabolic response (CR) as a result

  • There was no difference in the overall survival (OS) in the patients with perioperative chemotherapy compared with the surgery-only group with resectable CRC-LM [3]

Read more

Summary

Introduction

The 5-year survival rate of patients with advanced colorectal cancer (CRC) that has metastasized to the liver is determined by the possibility of resection of the primary tumor and liver metastases (LM). Despite a high rate of recurrence, 5- and 10-year overall survival are, respectively, 33% and 23% with a wide use of repeat hepatectomies and extrahepatic resections (median survival of 39 months) [7]. This strategy has become incorporated in the treatment of CRC with LM, randomized studies that demonstrate the superiority of this approach are lacking. We here report on a case where HAI of 5-FU-based chemotherapy could downstage the initially unresectable CRC-LM and rendered the patient amenable for hepatectomy achieving an overall survival of more than 5 years

Case Presentation
Findings
Discussion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call